NRX Pharmaceuticals Q2 2024 GAAP EPS $(0.75) Misses $(0.58) Estimate
Portfolio Pulse from Benzinga Newsdesk
NRX Pharmaceuticals (NASDAQ:NRXP) reported a Q2 2024 GAAP EPS of $(0.75), missing the analyst consensus estimate of $(0.58) by 29.31%. However, this is an improvement from the $(1.21) per share loss in the same period last year.
August 14, 2024 | 8:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NRX Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.75), missing the analyst consensus estimate of $(0.58) by 29.31%. Despite the miss, the loss is an improvement from $(1.21) per share in the same period last year.
The significant miss on EPS estimates is likely to negatively impact NRXP's stock price in the short term. However, the improvement from last year's loss may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100